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Membrane complement (C)1 receptors specific for different parts of the C3 molecule 
and  for/~IH, C5a,  and Clq have been  described on  a  variety of different cell types 
(1). CR1, specific for C3b and C4b,  and CRz for C3d have been isolated and shown 
to  be  glycoproteins of 205,000  Mr  and  72,000  Mr,  respectively (2-4).  Recently,  the 
fllH receptor also was isolated successfully using an anti-/~lH idiotypic antibody (5). 2 
Specific antibodies to isolated C  receptors indicated that a common structure for CR1 
is shared with erythrocytes, lymphocytes, monocytes, and neutrophils (2, 3)  and that 
CR~  is  restricted  to  B  lymphocytes  (4).  Because  earlier  studies  had  shown  that 
monocytes  (6,  7)  and  neutrophils  (8)  bound  EAC1-3d,  it  was  thought  that  these 
phagocytic cell types expressed a C3d-specific receptor that was similar to lymphocyte 
CR2. However, it now appears likely that the EAC 1-3d reagents used in these previous 
studies contained bound C3bi and little or no bound C3d.  Previously, EAC 1-3d were 
prepared by treatment of EAC 1-3b with purified C3b inactivator (C3bINA)  because 
it was believed that C3bINA removed C3c  from  the complexes, leaving only bound 
C3d.  Subsequently,  it  was  demonstrated  that  cleavage  of  fluid-phase  C3b  with 
purified C3bINA  (9)  resulted in formation of the C3bi  fragment, and that  EAC1-3b 
or EC3b  treated with  purified C3bINA contained  only C3bi  (EAC1-3bi or EC3bi) 
and no C3d  (10).  Further cleavage of C3bi into C3c and C3d required trypsin (9) or 
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albumin (BSA), 3.2% dextrose, 35 mM veronal buffer, pH  7.2, with  20 mM EDTA, and 0.2% sodium 
azide; C; complement;  C3b,  181,000 Mr fragment of C3; C3bi, C3bINA-cleaved C3b; C3c, 140,000 Mr 
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plasmin (11), suggesting that if these enzymes were present in serum, EAC prepared 
with serum might contain bound C3d as well as C3bi or only bound C3d. (Terms are 
defined in abbreviations list.) 
In the present study, various cell types were examined for binding of complexes 
that contained only C3bi or only C3d. Neutrophils, monocytes, and erythrocytes were 
found to bind C3bi but not C3d and to express a  receptor for C3bi (CR3)  that was 
distinct from  CR2  and specific for a  site contained in the  C3bi molecule that  was 
outside of the d  region. 
Materials and Methods 
Leukocytes and E~ythrocytes.  Heparinized blood  was  obtained from  normal  volunteers or 
patients with leukemia. Tonsils were obtained from patients undergoing routine tonsillectomy. 
Normal blood mononuclear cells and neutrophils were isolated on a two-step Ficoll-Hypaque 
density gradient (1.08 g/ml and 1.105 g/ml) (3, 8), and monoeytes were either depleted from 
mononuclear  cell fractions with Sephadex G- 10 (Pharmacia Fine Chemicals, Div. of Pharmacia 
Inc., Piscataway, N. J.)  (12) or purified on Percoll gradients (13). Immature myeloid cells were 
isolated from leukemic blood on a six-step Ficoll-Hypaque gradient (8). After two washes with 
phosphate-buffered saline (PBS), erythrocytes and each leukocyte type were resuspended at 4 
×  10  cells/ml in 35 mM veronal buffer, pH 7.2, containing 1% bovine serum albumin (BSA), 
20 mM EDTA, 3.2% dextrose,  and 0.2% sodium azide (BDVEA; 6 mS at  22°C).  Raji and 
Daudi leukemic lymphoblastoid cells and the BF lymphoblastoid line derived from normal 
lymphocytes were maintained in RPMI 1640 supplemented with 10% fetal bovine serum and 
antibiotics. 
Purification of C Components and Preparation of C3 Fragments.  C3, factor B, fl 1  H, nephritic factor, 
and C3bINA were purified as previously described (14, 15). Factor D was purified as described 
by LaSavre et al. (16). C3b-Sepharose was generated by mixing together 600 mg of C3 in 10 
mM EDTA-PBS with a 0.24% weight ratio of trypsin in the presence of 75 ml of activated-thiol 
Sepharose (Pharmacia Fine Chemicals) in a total volume of 150 ml (17). After 15 rain at 37°C, 
trypsin was inhibited by addition of a threefold molar excess of soybean trypsin inhibitor (STI) 
and then the disulfide-linked  C3b-sepharose was washed three times by centrifugation with ice- 
cold  10 mM EDTA-PBS. Elution of the C3b-Sepharose with l-cysteine demonstrated 6 mg of 
C3b per ml of gel. C3bi-Sepharose was formed by treatment of the C3b-Sepharose in 20 mM 
EDTA-DGVB (3.7 mS at 22°C), with a weight ratio of 50% ~IH and 4% C3blNA for 6 h at 
37~C,  followed  by  four washes  with  1.0  M  NaC1 in  PBS.  C3d-Sepharose was  formed  by 
treatment of C3b-Sepharose with trypsin (17) or elastase. With elastase, 8.5 ml of C3b-Sepharose 
was treated with an 8% weight ratio of purified porcine elastase (18) in 20 mM Tris/HC1, pH 
8.7, for 3 h at 37°C, followed by a second addition of 8% elastase and another 3 h at 37°C. The 
C3d-Sepharoses formed with each enzyme were then washed three times with ice-cold veronal- 
buffered saline (VBS). The wash supernatants were then concentrated to  10 ml with a UM-2 
membrane (Amicon Corp., Scientific Sys. Div. Lexington, Mass.)  and chromatographed on a 
5 ×  90-cm column of Sephadex G-75 (Pharmacia Fine Chemicals) in VBS. Four protein (A280) 
peaks were detected, separately pooled, and concentrated with a UM-2 membrane. Analysis by 
sodium dodecyl sulfate-polyacrylamide  gel electrophoresis (SDS-PAGE) (19) demonstrated that 
the first peak from the G-75 column contained C3c (20) and the second peak contained trypsin 
or elastase,  whereas no Coomasie Blue-stained protein bands were detectable in the third and 
fourth peaks with 15% polyacrylamide. These last two small C3 fragment pools contained no 
detectable intact C3c  or C3d  by SDS-PAGE. A  small C3  fragments preparation was  also 
generated by treatment of water-lysed EC3bi stroma with plasmin-Sepharose. Purified plas- 
minogen (21) was coupled to 5 ml of Sepharose CL-4B (22) at a ratio of 10 mg enzyme per ml 
of gel and then after activation of a 50% gel suspension with urokinase (14), was mixed on a 
o  I0  tube rotator for 60 rain at 37  C with 4 ×  10  EC3bi stroma that contained 1.2 X  10  ~ C3bi 
molecules per cell. The supernatant was then collected by centrifugation, concentrated with a 
UM-2 membrane, and chromatographed on Sephadex G-75 in a similar manner as were  the 
trypsin and elastase C3 fragments. The C3b-, C3bi-, and C3d-Sepharoses were each eluted with 98  MEMBRANE RECEPTORS  FOR  C3bi 
20 mM cysteine and the liberated C3 fragments dialyzed against BDVEA (prepared without 
BSA).  Analysis of each  C3  fragment by  SDS-PAGE under reducing conditions with  12% 
polyacrylamide demonstrated the known Mr chain structures (23): 3 C3b, 115,000 a' and 75,000 
fl; C3bi, 80% iC3b3  (41,000 a'4)  and 20%  iC3b2  (75,000 fl, 68,000  Or'a,  and 43,000  a'2); C3c 
(from  elastase  digest  only),  75,000  /~,  43,000  a'2,  and  29,000  a'3;  and  C3d,  30,000  a'5. 
Furthermore, no C3b was detected in the C3bi nor in the C3c, and no C3d was detected in the 
C3bi. 
Preparation of C3-coated Sheep Erythrocytes (EC3)  and Fluorescent Microspheres (C3-ms).  EC3b, 
EC3bi, and EC3d were  prepared as previously described (14, 24)  and contained 1.5 to 2.5 × 
104  bound C3  molecules per cell,  as  determined by the  uptake of 125I-monoclonal anti-C3 
(Bethesda Research Laoraories, Rockville, Md.). Coumarin (green) and rhodamine (red) stained 
fluorscent 0.9-#m Diam microspheres (Covalent Technology Corp., Redwood City, Calif.) were 
coated with isolated C3b, C3bi, and C3d fragments forming C3b-ms, C3bi-ms, and C3d-ms 
(25). 300/.tl of a  1.4% suspension of microspheres in PBS were mixed with 100/zl of C3b, C3bi, 
or C3d (400/zg/ml) and incubated at 25°C for  1 h on a tube rotator. The C3-ms were  then 
washed three times with 1% BSA/PBS by centrifugation for  10 min in a Beckman Microfuge 
(Beckman Instruments, Inc., Palo Alto, Calif.), resuspended in 3.0 ml of BDVEA containing 
1.0 mM phenylmethylsulfonyl fluoride (PMSF), and sonicated briefly until a single particle 
suspension was obtained. 
Preparation of Antibodies Specific for  CR1, CR2, C3c, and C3d. Rabbits were  immunized with 
purified CRx (26), CR2 (4), trypsin-generated C3c and C3d (14), and the F(ab')2, Fab', or Fab 
fragments of the isolated IgG antibodies were prepared by pepsin or papain cleavage (3, 4, 14). 
Assay of C Receptors. C receptors  were assayed by rosette formation with EC3 (1) or C3-ms in 
BDVEA. For C3-ms rosette assay,  100 ~1 of cells at 4 X 10  s cells/ml were mixed with 100/d of 
C3-ms in a  10 ×  75-mm plastic tube and placed on a tube rotator with horizontal axis for  15 
min at  37°C. Alternatively, the 200-/zl mixture of cells and C3-ms were pelleted together at 
1,000 g for 5 rain and incubated as a pellet for 5 rain at 370C. Next, the unbound C3-ms were 
removed from the cell suspension (or resuspended cell pellet) by layering the 200/~1 of cells onto 
4 ml of 6% BSA in PBS in another 10 ×  75-mm plastic tube and centrifuging at 200 g for  10 
min at room temperature. After aspiration of the supernatant, the cell pellet was resuspended 
in residual wash  fluid by shaking the  tube gently, and the cells were examined for  bound 
fluorescent  beads  by  standard  fluorescence  microscopy  techniques.  With  leukocytes,  cells 
binding five or more C3-ms were  considered positive, whereas with erythrocytes, a  positive 
cutoff of three or more bound C3-ms was used. 
For assay of the morphology of immature myeloid cell EC3 rosettes, Wright-Giemsa stained 
smears of rosette suspensions were prepared and analyzed as previously described (8). 
Assay for C Receptor Specificity.  A pellet of 4 ×  10  ~ C-receptor cells in a  10 ×  75-mm plastic 
tube was resuspended in 100/~1 of either BDVEA or F(ab')2 anti-CR1 (1 mg/ml), F(ab')z-anti- 
CR2 (3 mg/ml), C3b (1.0 mg/ml), C3bi (0.7 mg/ml), elastase-generated C3c (2.5 mg/ml), or 
trypsin-generated C3d  (0.5 mg/ml) diluted in BDVEA, incubated at  37°C for  10 min, and 
assayed for C-receptors by addition of 100 #1 of EC3 or C3-ms in BDVEA. Alternatively,  pellets 
of 2 ×  l0 7 EC3 were treated with 100/d of BDVEA or Fab anti-C3c (100 #g/ml) or Fab anti- 
C3d (3 mg/ml) in BDVEA, incubated for 20 rain at 37°C, and then tested for rosette formation 
with 100/LI of C-receptor cells. 
Assay for Enhancement of EC3bi Rosette Formation by Protease Inhibitors and Anti-Elastase.  Cell 
pellets of 4 ×  105 leukocytes in 10 ×  75-mm plastic tubes were resuspended in 100/zl of various 
concentrations  of either protease inhibitors  or rabbit IgG anti-human  neutrophil elastase (kindly 
provided by Dr. John Spitznagel, Emory University, Atlanta, Ga.), previously absorbed six 
times with a  10% packed volume of sheep erythrocytes. Next, each inhibitor or anti-elastase 
treated cell suspension was assayed  for EC3bi rosette formation in the usual manner. 
Double-Label Assay of Lymphocytes  for CR~ and Surface Immunoglobulin (I~), or Leu-1 and 3A 1 T Cell 
Antigens, or OKM-1 Monocyte-Null Cell Determinant.  A pellet of 1 ×  10  lymphocytes was treated 
simultaneously for 20 rain at room temperature with 25/zl of F(ab')2-anti-CR2 (3 mg/ml) and 
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a  fluorescein isothiocyanate (FITC)-linked stain specific for either surface Ig, Leu-1  or 3A1 T 
cell  antigens,  or  OKM-1  monocyte-null  cell  determinant,  and  then  examined  for  rosette 
formation with  rhodamine-stained  C3bi-ms.  For Ig staining,  cells were treated  with  25/zl of 
F(ab')2-anti-IgM, IgD, IgA, IgG-fluorescein (N. L. Cappel Laboratories, Cochranville, Pa.). For 
T  cell staining, 'cells were treated with  a  45-p.1 mixture containing  2.0/~g of protein-A-FITC 
(Pharmacia Fine Chemicals) and  1.0 p.g of either mouse IgG-anti-Leu-1  (B-D FACS Systems, 
Beeton, Dickinson & Co., Sunnyvale, Calif.), mouse IgG-anti-3A1  (27)  (kindly donated by Dr. 
George  Eisenbarth,  Duke  University,  Durham,  N.  C.),  or  mouse  IgG-anti-OKM-I  (Ortho 
Pharmaceutical, Raritan, N. J.). Next, to enhance the monoclonal antibody FITC staining, the 
washed  cells  were  stained  in  addition  with  FITC-F(ab')2-anti-mouse  IgG  (N.  L.  Cappel 
Laboratories).  Finally, the fluorescein-stained cells were resuspended  in  100/zl of BDVEA and 
assayed for CRs by addition of 100 ~1 of rhodamine-C3bi-ms. Cells were examined sequentially 
for fluorescein and/or rhodamine staining.  In each case the anti-CR2-treated  cells were also 
tested for complete absence of the ability to rosette with C3d-ms. 
Results 
Binding of C3bi Complexes to  Various Leukocyte Types and Erythrocytes.  Both EC3bi and 
C3bi-ms bound to a  proportion of lymphocytes, erythrocytes, neutrophils, and mon- 
ocytes (Table I). In all cases, C3bi-ms bound to a greater percentage of cells than did 
EC3bi. The increased binding of C3bi-ms was particularly apparent with erythrocytes, 
92% of which bound C3bi-ms,  and  10% or less bound  EC3bi.  Only lymphoid cells 
bound C3d complexes. Immature monocytes and myeloid cells isolated from patients 
with  either acute  monocytic leukemia or chronic myelogenous leukemia  were also 
negative for binding of C3d complexes. 
Specificity of C3bi-dependent Rosette Formation.  The specificity of C3bi complex bind- 
ing was examined by assays for inhibition of rosette formation, either by treatment of 
the C receptor cells with Fab' anti-C-receptor antibodies or fluid-phase C3 fragments 
(Table II) or by treatment of the C3 complexes with Fab anti-C3c or Fab anti-C3d 
antibodies  (Table III). With  all cell types, C3b-ms  rosettes were inhibited by anti- 
CR1, fluid-phase C3b and fluid-phase C3c but not by anti-CR2, fluid-phase C3bi, or 
fluid-phase C3d. By contrast, C3bi-ms rosettes were not inhibited by anti-CR1, fluid- 
phase C3b, or fluid-phase C3c. Thus, neither C3bi-ms nor fluid-phase C3bi bound to 
CR1 on any cell type. With erythrocytes, neutrophils, and monocytes, C3bi-ms rosettes 
were inhibited by fluid-phase C3bi but not by anti-CR1, anti-CR2, fluid-phase C3b, 
C3c, or C3d. Therefore, with these nonlymphoid cell types, C3bi-ms were bound to 
TABLE  I 
EC3 and C3-ms Rosette Formation with Lymphocytes, E(ythrocytes, 
Neutrophils, and Monocytes 
EC3b  C3b-ms  EC3bi  C3bi-ms  EC3d  C3d-ms 
Blood lymphocytes 
Lymphoblastoid lines 
Raji  0  0 
Daudi  0  0 
BF  98  L00 
Erythrocytes  75  95 
Neutrophils  95  100 
Monocytes  85  95 
%  %  %  %  %  % 
16  17  [0  12  7  9 
99  100  98  100 
84  96  86  95 
98  99  97  98 
10  92  0  0 
75*  89*  0  0 
84  91  0  0 
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TAnLE II 
Inhibition of C3-ms Rosettes by Anti-C3 Receptor Antibodies and 
Fluid-Phase C3 Fragments 
Inhibition of rosette formation by 
C3 
C receptor cell type  complex  Anti-  Anti-  Fluid-phase* 
CRI  CRz  C3b  C3bi  C3c  C3d 
%  %  %  %  %  % 
Erythrocytes  C3b-ms  100  0  100  0  48  0 
C3bi-ms  0  0  0  85  0  0 
Neutrophils  C3b-ms  100  0  62  0  32  0 
C3bi-ms  0  0  0  80  0  0 
Monocytes  C3b-ms  100  0  60  0  27  0 
C3bi-ms  0  0  0  50  0  0 
Raji lymphoblasts  C3bi-ms  0  78  0  I00  0  71 
C3d-ms  0  100  0  100  0  100 
* C3b, 500 #g/ml; C3bi, 350 #g/ml; C3c (elastase), 1.25 mg/ml; C3d (trypsin), 
250 #g/rnl. 
TABLE  III 
Inhibition of EC3 Rosettes with Fab-Anti-C3c and Fab-Anti-C3d 
Cell type  EC3 type 
Inhibition of rosettes by 
Anti-C3c  Anti-C3d 
%  % 
Erythrocyte  EC3b  100  0 
EC3bi  100  I00 
Neutrophils and  EC3b  100  0 
Monocytes  EC3bi  100  100 
Raji or Daudi  EC3bi  100  100 
Lymphoblasts  EC3d  0  100 
a  receptor that was distinct from CR1 and CR2, herein designated CR3. Lymphocytes 
differed  from  other  cell  types  in that  C3bi-ms rosettes  were  partially inhibited by 
anti-CR2 and  fluid-phase C3d.  Also,  lymphocyte-C3d-ms rosettes  were  completely 
inhibited by fluid-phase C3bi as well as by anti-CR2 or fluid-phase C3d. Thus, with 
lymphocytes that expressed CR2, C3bi complexes were bound to CR2 by way of the 
d region of the intact C3bi molecule. However, with concentrations of up to 5 mg/ml 
of Fab' anti-CR2 or 1.0 mg/ml of fluid-phase C3d, lymphocyte C3bi complex rosettes 
were never inhibited completely. This indicated that lymphocytes expressed CR3 in 
addition to CR2 and that  both C  receptor types were responsible for binding C3bi 
complexes to lymphocytes. 
Fab anti-C3c and Fab anti-C3d both  inhibited EC3bi rosette  formation with all 
cell types  (Table III). Fab anti-C3d did not inhibit EC3b rosette formation, despite 
the finding that Fab anti-C3d inhibited the agglutination of EC3b by IgG anti-C3d 
and thus bound to the d  region of intact C3b. 
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other smaller C3 fragments generated by proteolysis of C3b or C3bi were examined 
for inhibition  of C3bi-ms rosette formation. Inhibition of neutrophil-EC3bi rosettes 
and human E-C3bi-ms rosettes was observed with the fluid-phase small C3 fragments 
pool generated with plasmin or trypsin but not with elastase. 
Inhibition  of  C3bi-dependent  Neutrophil  Rosette Formation  by  Secreted Neutrophil 
Elastase.  Because of the known proteolytic sensitivity of C3bi  (9)  and  because the 
bound product of C3bi digestion, C3d, was unreactive with neutrophils and mono- 
cytes, protease inhibitors were added to rosette assays to protect the C3bi-complexes 
from proteolysis into CR3-unreactive C3d complexes (Table IV). Both STI and PMSF 
enhanced neutrophil-EC3bi rosette formation from 5% up to 76-89%, whereas benz- 
amidine and epsilon amino caproic acid caused no rosette enhancement. These same 
protease inhibitors had no effect on EC3bi rosette formation with blood monocytes or 
lymphocytes.  Because  neutrophils  were  known  to  secrete  elastase  in  response  to 
opsonized bacteria (28) and because human neutrophil elastase was known to cleave 
C3bi into C3c and C3d (20), an antibody to human neutrophil elastase was examined 
for its ability to enhance neutrophil-EC3bi rosette formation (Table IV). Anti-elastase 
produced the same rosette  enhancement  as  did  STI and  PMSF.  In  the  absence of 
protease inhibitors or anti-elastase, EC3bi that had been incubated with neutrophils 
for 60 min at 37°C were no longer agglutinated by anti-C3c, whereas agglutination 
by anti-C3d and Raji rosette formation were undiminished. 
Acquisition of Elastase-secreting Ability  with Neutrophil Maturation.  Neutrophils  from 
the blood of a patient with chronic myelogenous leukemia and blood count of 2 ×  105 
neutrophils per/~1 were fractionated into immature (band-form nucleus) and mature 
polymorphonuclear cells  and examined for EC3bi rosette formation with increasing 
concentrations of STI (Table V). In the absence of STI, 49% of band-form neutrophils 
formed rosettes with  EC3bi, whereas high-density polymorphs did  not form EC3bi 
TABLE  IV 
Enhancement of Neutrophil-EC3bi Rosette Formation with Protease Inhibitors 
and Anti-Elastase 
Protease inhibitor  Neutrophil-EC3bi 
rosette formation 
% 
Buffer control  5 
STI 
1.0 mg/ml  88 
0.5 mg/ml  89 
0.25 mg/ml  70 
0.10 mg/ml  35 
0.05 mg/ml  25 
PMSF 
2.0 mM  36 
[.0 mM  76 
0.5 mM  40 
Anti-elastase 
1/5  87 
1/10  87 
1/20  79 
1/40  38 102  MEMBRANE  RECEPTORS  FOR  C3bi 
TABLE V 
Neutrophil Cell Density and Maturation-linked Requirement  for Increased 
Amounts of STI to Allow EC3bi Rosette Formation 
Neutrophil density in g/ml 
(predominant  morphology) 
1.07  1.09  1.105  1.12 
(bands)  (PMN)  (PMN)  (PMN) 
%R *  %R  %R  %R 
Buffer control  49  40  10  0 
ST1 
25 ~g/ml  51  54  20  10 
50 p.g/ml  50  70  25  19 
200/Lg/ml  50  69  49  39 
400/zg/m|  51  68  92  68 
800 ~g/ml  49  71  95  97 
1 mg/ml  51  69  94  98 
* Percent EC3bi rosette formation. 
TABLE VI 
Expression of CR3 on Lymphocytes Detected by C3bi-ms Rosette Formation 
with Anti-CR2-treated Cells 
Cell type 
Rosette formation with 
C3d-ms  C3bi-ms 
%  % 
Blood lymphocytes (8)  9  12 
+ anti-CR2  0  3.5 
Tonsil lymphocytes (3)  54  59 
+ anti-CR2  0  27 
Raji lymphoblasts  99  99 
+ anti-CR2  0  40 
Daudi lymphoblasts  95  96 
+ anti-CR2  0  32 
BF lymphoblasts  59  56 
+ anti-CR2  0  9 
rosettes.  With  the  band-form  neutrophils,  STI  did  not  increase  the  proportion  of 
EC3bi rosettes. However, with neutrophils isolated at a  1.09 g/ml density, 50 Ilg/ml 
STI was  required  for  maximum  enhancement  of EC3bi  rosette  formation,  whereas 
with  1.105 g/ml neutrophils and  1,12 g/ml neutrophils, 400/~g/ml and 800/~g/ml of 
STI were required, respectively (Table V). 
Expression  of CR~  on  Different  Lymphocyte  Subsets.  Lymphocytes  from  blood  and 
tonsils and various B type lymphoblastoid lines were treated with sufficient anti-CR2 
to inhibit C3d-ms binding completely and then assayed for binding of C3bi-ms (Table 
VI). The majority of C3bi-ms-binding cells expressed only CRz and did not express 
CRa,  as anti-CR2 treatment  of ceils produced 54-84%  inhibition of C3bi-ms rosette 
formation.  Among normal blood lymphocytes, only  1.5-4.5%  (average 3.5%)  of cells 
expressed CRa,  and  these were  apparently distinct  from  the  CR2-bearing cells that 
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cytes from six normal individuals demonstrated that 86% of cells bearing CRz or CR3 
also  expressed membrane Ig  detectable with  F(ab')2-anti-Ig.  No  CR2-positive cells 
were detected that  expressed either Leu-1  or 3AI  T  cell determinants.  Among the 
CRa-positive blood lymphocytes, 5% of cells stained with either anti-Leu-1  or anti- 
3A1,  and  16% of cells stained  with anti-OKM-1.  Tonsils contained a  considerably 
higher proportion of CR3-bearing cells than did peripheral blood. However, unlike 
blood lymphocytes, the majority of tonsil CRa-positive cells expressed CR2 because 
the percentage of cells binding either C3bi-ms or C3d-ms was nearly equal. All three 
B type lymphoblastoid cell lines examined expressed CR3 on a proportion of the cells. 
Discussion 
The major finding in the present study is that lymphocytes, monocytes, neutrophils, 
and erythrocytes express a C3bi-specific membrane C  receptor (CRa)  that is distinct 
from CR1 and CR2. CRa is specific for C3bi and unreactive with C3b, C3c, and C3d. 
Neutrophils and monocytes lack detectable CR2 at all stages of maturation and bind 
C3bi complexes exclusively to CRa. Neutrophils begin to express CRa at the myelocyte 
stage and the receptor is fully expressed on polymorphs. Peripheral blood lymphocytes 
bind C3bi complexes primarily to CRy, and the cells that express CRa are a separate 
B cell subset from the CR2-bearing B cells. 
C receptors were assayed with either sheep erythrocytes or fluorescent microspheres 
coated with specific C3  fragments  (EC3 or C3-ms).  C3-ms had  distinct advantages 
over EC3. First, probably because of their smaller size, C3-ms were more sensitive to 
cells known to have a low number of C-receptors per cell. C3b-ms and C3d-ms bound 
to nearly all  human  erythrocytes and  Daudi  cells respectively, whereas  EC3b  and 
EC3d bound to fewer of these two cell types. Also, C3-ms could be prepared with very 
small amounts of pure C3 fragments that had been previously characterized fully by 
SDS-PAGE. 
The receptor specificity of C3 complex binding to different cell types was investi- 
gated by rosette inhibition studies in which either the C  receptor cells were treated 
with anti-CRa, anti-CR2, fluid-phase C3b, C3bi, C3c, or C3d, or alternatively the C3 
complexes were treated with anti-C3c or anti-C3d. In experiments that examined the 
binding  specificity of C3b  complexes or  fluid-phase  C3b,  it  was  essential  to  use 
inhibitors of proteolysis of C3b  in  the  rosette assay buffer.  Lymphocytes (14,  29), 
monocytes (30,  31), and neutrophils (32) secrete endogenous fllH and C3bINA that 
may convert bound or fluid-phase C3b  into C3bi.  Neutrophils also secrete elastase 
that  may  cleave  C3b  into  C3d  (20).  EDTA  and  sodium  azide  were  used  in  the 
rosetting buffer (BDVEA)  because they had  been shown  previously to inhibit  the 
release of B  cell C3bINA  and fllH  (14)  and  also seemed to inhibit  monocyte and 
neutrophil release of these components. In addition, STI was added to the BDVEA 
buffer to inhibit  neutrophil elastase activity. C3bi  complexes did  not  bind  to CR1 
because C3bi-ms rosettes were not inhibited by anti-CR1, fluid-phase C3b, or fluid- 
phase  C3c,  whereas  these  same  materials  did  inhibit  C3b-ms  binding  to  CR1.  In 
addition, isolated fluid-phase a25I-labeled CRx does not bind to EC3bi, whereas fluid- 
phase CR1 does bind to EC3b (3). The C3bi complex binding activity of erythroeytes, 
monocytes, and  neutrophils  was  also  distinct  from CR2  activity because  these cell 
types did not bind C3d complexes, nor were C3bi-ms rosettes inhibited by anti-CR~ 
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complexes  were  bound  primarily  to  CR2.  Lymphocyte  binding  of  C3bi-ms  was 
inhibited  by anti-CR2  and  fluid-phase C3d  as well  as by fluid C3bi.  Furthermore, 
lymphocyte-C3d-ms rosette formation was inhibited completely by fluid-phase C3bi 
as  well  as  by  fluid  C3d  and  anti-CR2.  A  portion  of lymphocytes  did  bind  C3bi 
complexes independently of CRz because treatment of lymphocytes with amounts of 
F(ab')2 anti-CR2 or fluid-phase C3d that were twofold to fourfold greater than that 
required for complete inhibition of C3d-ms binding only produced 50-84% inhibition 
of C3bi-ms binding. Thus, lymphocytes bound C3bi complexes either to CRz by way 
of the  d  region  of the  intact  C3bi  molecule  or by way  of a  distinct  C3bi-specific 
receptor  that  was  distinct  from  CR2.  The  C3bi-specific  binding  activity  that  was 
distinct from CR2 was designated CR3 with all cell types. 
Because C3b does not bind to CR3, the CR3 binding site in the C3bi molecule must 
be exposed by cleavage of C3b with the C3bINA. Thus, CR3 has a  similar binding 
specificity as bovine conglutinin  (33). Unlike conglutinin  (34)  however, CRz activity 
was  not  inhibited  by  EDTA  or  n-acetyl-o-glucosamine  (G.  D.  Ross,  unpublished 
observation).  Because  neither  fluid-phase  C3b,  C3c,  nor  C3d  inhibited  the  CR3- 
binding activity of C3bi-ms, the CR3 binding site in the C3bi molecule must be either 
destroyed, liberated, or covered by proteolysis of C3bi. To determine whether a smalI 
CR3-specific fragment could be generated that was distinct from intact C3c and C3d, 
bound C3b or C3bi was digested into C3c and C3d with elastase, trypsin, or plasmin, 
and then  after removal of the  intact  C3c  and C3d  fragments, the  remaining small 
fragment pools were examined for inhibition of C3bi complex binding to neutrophil 
or erythrocyte CR3. Inhibition of CR3 was demonstrated by the small C3 fragments 
pool generated with plasmin and trypsin but not with elastase.  Elastase is known to 
have a  more limited  number of digestion  sites  in  the  C3  molecule than  has either 
plasmin or trypsin (11,  20, 23).  In particular, elastase digests only the a  chain of C3 
or C3b  (20), whereas trypsin cleaves both the 0t and the/3 chains of C3 or C3b, and 
plasmin  cleaves both  the  a  and  fl chains  of C3bi  (11).  Because  none  of the  three 
proteases digest C3d, the data suggests the possibility that the CR3 binding site may 
be folded  within  the  intact  C3c  fragment  and  not  exposed  until  cleaved  from the 
molecule with trypsin or plasmin. Likewise, the CR1 binding site is apparently folded 
within the C3bi molecule and then re-exposed in the C3c fragment that is excised by 
proteolysis of C3bi. This is because fluid C3c but not fluid C3bi inhibited CR1-C3b- 
ms  rosette  formation.  Available  data  (35,  36)  suggest  the  possibility  that  the  C3e 
fragment may contain the CR3 binding site. C3e was shown to be removed from C3c 
by extensive trypsin digestion, and 1251-C3e was shown to bind to neutrophils  (36). 
Previously,  it  had  been  shown  (8)  that  neutrophils  acquired  the  ability  to  bind 
EAC 1-3bi at approximately the myelocyte stage of maturation, and then as the cells 
matured into polymorphonuclear cells this ability was lost. In these former studies, an 
EAC l-3d reagent was used that is now recognized to have actually been an EAC 1-3bi 
reagent  because  it  was  prepared  with  purified  C3bINA  without  the  additional 
proteolysis  required  to  cleave  the  bound  C3bi  fully  to  C3d.  The  present  study 
demonstrated that the loss of ability of mature neutrophils to rosette with EC3bi  (or 
EAC1-3bi) was not due to a loss of CR3 but rather to the maturation-linked acquisition 
of the ability to secrete elastase that cleaved the reagent EC3bi into CR3-unreactive 
EC3d.  Several  lines  of  evidence  supported  this  conclusion.  First,  EC3bi  rosette 
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human neutrophil elastase. STI and PMSF also allowed EC3bi rosette formation with 
mature neutrophils.  Second, in  the absence of protease inhibitors,  EC3bi  that  had 
been incubated with neutrophils lost all detectable C3c antigens while retaining C3d 
antigens and the ability to bind to lymphocyte CR2. This indicated that neutrophil 
enzymes cleaved EC3bi  to EC3d.  Finally, when neutrophils were fractionated into 
cells with band form nucleus and polymorphonuclear cells, it was found that STI did 
not enhance EC3bi rosette formation with band form cells, whereas with polymorphs, 
more STI was required to allow EC3bi rosettes with high density (1.12 g/ml) mature 
polymorphs than with low density (1.09 g/ml) less mature polymorphs. Elastase has 
been  detected  in  azurophilic  myeloid cell  granules  by  immunofluorescence at  the 
promyelocyte stage of maturation  (37).  However, promyelocyte elastase is probably 
not secreted, and polymorphs apparently release azurophilic granule enzymes only at 
the site of contact with serum-opsonized bacteria (28). Because binding of opsonized 
bacteria probably involves Fc receptors, CRI, and CRa, one of these three types of 
receptors on mature cells may have the ability to trigger elastase secretion. Because of 
this  elastase-secreting  activity,  neutrophils  in  vivo  are  probably  unable  to  bind 
particles  that  contain  only  C3bi,  and  therefore  it  is  presumed  that  CRa  is  not 
important for neutrophil phagocytosis. Because CRa apparently binds a small trypsin- 
or plasmin-derived C3bi fragment, it is possible that such an active fragment may be 
generated by C3bi proteolysis in vivo, and that this fragment may be responsible for 
triggering some neutrophil function other than phagocytosis. 
Monocytes resembled neutrophils in that they expressed CRa and CRa and lacked 
detectable CR2. Unlike neutrophils, monocytes did not require protease inhibitors to 
allow EC3hi rosette formation. Furthermore, other studies have demonstrated that 
human macrophages (31)  and rat mast cells (38)  ingest C3bi complexes much more 
efficiently than C3b complexes. Thus, these other phagocyte types differ from neutro- 
phils in that CRa appears to be more important than CR~ for phagocytosis in vivo. 
CRa were also detected on the majority of human erythrocytes. In the past, human 
erythrocytes were thought to express only CR1 and not to bind C3bi or C3d complexes. 
Gaither  et  al.  had  noted  reduced  human  erythrocytes  immune  adherence  with 
EAC43bi  as compared with  EAC43b  (39).  However, it was  not clear whether this 
C3bi-dependent  immune adherence was  due to a  distinct  C3bi-specific receptor or 
rather a low affinity binding of C3bi to CR1. Indeed, human E-rosette formation with 
EC3bi or EAC1-3bi is difficult to demonstrate, as it is such a  weak reaction. In the 
present  study, C3bi-ms were prepared with purified C3bi  fragments containing no 
detectable C3b by SDS-PAGE and were shown to bind to nearly all human eryth- 
rocytes in the presence of amounts of anti-CR1 that were sufficient to inhibit C3b-ms 
binding completely. 
Cells of the human renal glomerulus apparently also express both CR1 and CR3. 
Carlo et al.  have demonstrated that  kidney cells bind both EAC43b  and  EAC43bi 
but not EAC43d  (40). Also, it has recently been demonstrated that  renal epithelial 
cells are fluorescence stained with F(ab')2 anti-CRx (M. Papamichail, J. D. Lambris, 
and G. D. Ross, unpublished observation). 
Lymphocytes differed from all the other cell types examined in that they expressed 
CR2 in addition to CRa, and C3bi complexes were primarily bound to CR2 rather 
than  to CRa.  For this  reason, specific assay of lymphocyte CRa  required complete 
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ms.  With peripheral blood tymphocytes, only 3.5% of anti-CR2-treated cells bound 
C3bi-ms. This finding indicated that  the majority of the  12.0% of C3bi-ms-binding 
cells did not express CR3 and expressed only CR2. Parallel assay of C3d-ms-binding 
cells confirmed that 9.0% of cells expressed CR2, so that the  12.0% C3bi-ms-binding 
cells consisted of 8.5% CR2 + CRy- cells, 3.0%  CR2-CR3 + cells, and only 0.5%  CRz + 
CR3  + cells.  Thus, CR2  + and CR3 + cells represented nearly distinct subsets.  Previous 
double-label studies with EAC 1-3hi  (41) and present studies with C3bi-ms indicated 
that the majority of CR2  + and/or CR3  + peripheral blood cells expressed membrane 
Ig detectable with F(ab')2-anti-Ig.  The same finding was made when CRz  + ceils or 
CR3  + cells were examined individually for Ig with C3d-ms or anti-CR~ and C3bi-ms, 
respectively. Among CRa  + blood nonadherent lymphoid-appearing cells, an average 
of 86% of cells expressed membrane Ig, whereas only 5% of these cells expressed either 
Leu-1 or 3AI T  cell-specific determinants, and  15% expressed OKM-1 determinants. 
The OKM-1  staining CR3 + cells probably represented either third population lym- 
phocytes (null cells), myeloid precursors, or promonocytes (42). Thus, the majority of 
CR3-bearing blood lymphocytes are B cells (3.0%),  whereas only 0.2% express T  cell 
determinants  and  0.6%  express  a  monocyte-null  lymphocyte  determinant.  Tonsil 
lymphocytes differed from blood lymphocytes in that one-half of the CR3 + cells also 
expressed CR2. This was because the proportions of C3bi-ms- and C3d-ms-binding 
cells were nearly equal, and anti-CR2 produced only 50% inhibition of C3bi-ms rosette 
formation. As  with  blood lymphocytes, the majority of CR3 + tonsil cells expressed 
membrane Ig, Three different B type lymphoblastoid lines also expressed CR3 + cells, 
though with all three lines, C3bi complexes were primarily bound to CRz. In previous 
studies of three different T  cell lymphoblastoid  lines and  several different lines  of 
normal activated T  cells maintained  in T  cell growth factor, no cells binding C3b, 
C4b,  C3bi,  or  C3d  complexes  were  observed  (G.  D.  Ross  and  G.  D.  Bonnard, 
unpublished observation). The only exception was the MOLT-4 T cell lymphoblastoid 
line  (43).  Taken together, the various data  indicate that  CR3  is primarily a  B cell 
marker. Recently, Perlmann et al. (44) have reported that the activity of lymphocytes 
functional in antibody-dependent cellular cytotoxicity (ADCC) was greatly enhanced 
by target cell-bound C3bi, whereas less enhancement was observed with bound C3b 
and C3d. Because it was also shown in other studies that ADCC lymphocytes lacked 
detectable membrane Ig determinants (45) and expressed either T cell (46, 47) or null 
cell markers (48), it appears possible that the small number of Ig-CR3  + cells detected 
in the present study may represent the cells functional in ADCC. 
The significance of a C3bi-specific receptor is not fully understood. Subsequent to 
C  activation, both bound and fluid-phase C3b are rapidly converted into C3bi, and 
some of this  C3bi  apparently  persists  in  serum  for several hours  (10)  before being 
degraded  into smaller C3  fragments.  Macrophages  (31)  and  mast  cells  (38)  ingest 
C3bi  complexes  much  more  efficiently  than  C3b  complexes.  Also,  bound  C3bi 
enhances  both neutrophil  phagocytosis of IgG-coated particles and  the  neutrophil 
superoxide  burst  (32).  However,  this  C3bi-dependent  enhancement  of neutrophil 
function requires addition of an inhibitor ofelastase, suggesting that bound C3bi may 
not have these functions in vivo. With the exception of ADCC cells, no function of 
lymphocyte CR3 has yet been demonstrated. Because C3bi can bind to either CR2 or 
CR3,  it  may be  possible  that  C3bi  complexes can  simultaneously  crosslink  B  cell 
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in  which  lymphocytes are  cultured  with  C3bi-ms  with  or without  Fab'-anti-CR2 
might be able to answer this question. 
Summary 
Cells expressing a membrane C receptor (CRs) specific for C3b-inactivator-cleaved 
C3b  (C3bi)  were  identified  by  rosette  assay  with  C3bi-coated  sheep  erythrocytes 
(EC3bi)  or C3bi-coated fluorescent microspheres  (C3bi-ms).  C3bi-ms, probably be- 
cause of their smaller size, bound to a  higher proportion of cells than  did  EC3bi. 
C3bi-ms bound to >90% of mature neutrophils, 85% of monocytes, 92% of erythro- 
cytes, and  12% of peripheral blood lymphocytes. Binding of C3bi-ms to neutrophils, 
monocytes, and erythrocytes was inhibited by fluid-phase C3bi, Fab anti-C3c, or Fab 
anti-C3d but was not inhibited by F(ab')2 anti-CR~  (C3b receptor) or F(ab')2 anti- 
CR2  (C3d  receptor)  nor  by  fluid-phase  C3b,  C3c,  or  C3d.  This  indicated  that 
monocytes, neutrophils, and erythrocytes expressed C3bi  receptors (CRs)  that were 
separate and distinct from CR1 and CR2 and specific for a  site in the C3  molecule 
that was only exposed subsequently to cleavage of C3b by C3b inactivator and that 
was  either destroyed, covered, or liberated by cleavage of C3bi  into C3c  and  C3d 
fragments. Lymphocytes differed from these other cell types in that  they expressed 
CR2 in addition to CRa. Lymphocyte C3bi-ms rosettes were inhibited from 50 to 84% 
by  F(ab')2-anti-CR2  or  fluid-phase  C3d,  whereas  C3d-ms  rosettes  were  inhibited 
completely by  F(ab')2  anti-CR2,  fluid-phase  C3bi,  or fluid-phase  C3d.  Thus,  with 
lymphocytes, C3bi was bound to CRa, and in addition was bound to CR2 by way of 
the intact d region of the C3bi molecule. In studies of the acquisition of C  receptors 
occurring  during  myeloid cell  maturation,  the  ability  to  rosette with  C3bi-coated 
particles was detected readily with immature low-density cells, whereas this ability 
was  nearly  undetectable  with  high  density  mature  polymorphonuclear cells.  This 
absence of C3bi binding to polymorphs was not due to a loss of the CR3 but instead 
was  due to the  maturation-linked  acquisition  of the  abiity to secrete elastase  that 
cleaved reagent  particle-bound C3bi  into CRs-unreactive C3d.  Neither neutrophils 
nor monocytes bound C3d-coated particles at any stage of maturation. Assay of CR3 
with mature neutrophils required inhibition of neutrophil elastase with either soybean 
trypsin inhibitor or anti-elastase antibodies, and the amounts of these elastase inhib- 
itors required to allow EC3bi rosette formation increased with neutrophil maturation. 
Because  lymphocytes  bound  C3bi  to  CR2  as  well  as  to  CRa,  specific  assay  of 
lymphocyte CR3 required saturation of membrane CR2 with Fab' anti-CR~  before 
assay  for  rosettes  with  C3bi-ms.  Only  3.5%  of anti-CR2-treated  peripheral  blood 
lymphocytes bound C3bi-ms. Therefore, among normal blood lymphocytes the ma- 
jority of the  12%  C3bi-ms-binding  cells expressed only CR2  (8.5%), and  the  small 
proportion of C3bi-ms-binding cells that expressed CR3 (3.5%)  represented a distinct 
subset  from the CR2  + cells.  Double-label assay indicated  that  3.0%  out  of 3.5%  of 
these  CRs-bearing  lymphocytes  were  B  cells  because  they  expressed  membrane 
immunoglobulins. Of the remaining CR3  + cells, 0.2% expressed either Leu-1 or 3A1 
T  cell antigens, and 0.6% expressed the OKM-1 monocyte-null lymphocyte determi- 
nant. 
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